XRTX:CC - XORTX Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (XRTX)
2023-09-04 20:00:00 ET
XORTX Therapeutics is now ranked among the top 10 undervalued stocks in the Healthcare sector on the TSX Venture Exchange.
- A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
- Valuation methodology provided by Stockcalc (see below)
Stocks in this category are held primarily for capital appreciation.
| Symbol | Name | Close Price ($) | Valuation ($) | Difference | Average Vol (30D) | Market Cap () | Yield (%) | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
| SVS | ||||||||
| Solarvest BioEnergy | ||||||||
| 0.03 | ||||||||
| 0.08 | ||||||||
| 0.05 (200.8%) | ||||||||
| 47841 | ||||||||
| 1.9 | ||||||||
| 0.0 | ||||||||
| 0.0 | ||||||||
| XRTX | ||||||||
| XORTX Therapeutics | ||||||||
| 0.90 | ||||||||
| 2.61 | ||||||||
| 1.71 (189.5%) | ||||||||
| 11281 | ||||||||
| 16.2 | ||||||||
| 0.0 | ||||||||
| 0.0 | ||||||||
| NDVA | ||||||||
| Indiva | ||||||||
| 0.04 | ||||||||
| 0.08 | ||||||||
| 0.05 (135.7%) | ||||||||
| 402504 | ||||||||
| 5.2 | ||||||||
| 0.0 | ||||||||
| 0.0 | ||||||||
| PHC | ||||||||
| Pathway Health | ||||||||
| 0.02 | ||||||||
| 0.05 | ||||||||
| 0.03 (132.7%) | ||||||||
| 1.9 | ||||||||
| 0.0 | ||||||||
| 0.0 | ||||||||
| NPTH | ||||||||
| NeuPath Health | ||||||||
| 0.14 | ||||||||
| 0.34 | ||||||||
| 0.19 (131.2%) | ||||||||
| 15890 | ||||||||
| 8.1 | ||||||||
| 0.0 | ||||||||
| 0.0 | ||||||||
| DOC | ||||||||
| CloudMD Software & Servs | ||||||||
| 0.15 | ||||||||
| 0.35 | ||||||||
| 0.20 (128.2%) | ||||||||
| 165203 | ||||||||
| 46.8 | ||||||||
| 0.0 | ||||||||
| 0.0 | ||||||||
| ROMJ | ||||||||
| Rubicon Organics | ||||||||
| 0.46 | ||||||||
| 0.95 | ||||||||
| 0.49 (107.6%) | ||||||||
| 14369 | ||||||||
| 26.2 | ||||||||
| 0.0 | ||||||||
| 0.0 | ||||||||
| NU | ||||||||
| NeutriSci International | ||||||||
| 0.01 | ||||||||
| 0.01 | ||||||||
| 0.00 (99.7%) | ||||||||
| 22794 | ||||||||
| 0.9 | ||||||||
| 0.0 | ||||||||
| 0.0 | ||||||||
| JUMP | ||||||||
| Leveljump Healthcare | ||||||||
| 0.07 | ||||||||
| 0.13 | ||||||||
| 0.06 (92.9%) | ||||||||
| 21681 | ||||||||
| 5.7 | ||||||||
| 0.0 | ||||||||
| 16.3 | ||||||||
| SBBC | ||||||||
| Simply Better Brands | ||||||||
| 0.27 | ||||||||
| 0.52 | ||||||||
| 0.25 (92.3%) | ||||||||
| 42172 | ||||||||
| 15.2 | ||||||||
| 0.0 | ||||||||
| 0.0 |
All data provided as-at market close September 01, 2023.
The list is sorted by stocks with the greatest percentage difference between valuation and price.
XORTX Therapeutics
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.
XORTX Therapeutics is listed under XRTX on the TSX Venture Exchange.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.
Stockcalc valuations ( https://www.stockcalc.com/Resources ) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:
- Discounted Cash Flow (DCF)
- Price & Other Comparables
- Multiples
- Adjusted Book Value (ABV)
- Analyst Consensus
Artificial Intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.